Graham Paterson Acquires 11,643 Shares of Diaceutics PLC (LON:DXRX) Stock

Diaceutics PLC (LON:DXRX) insider Graham Paterson bought 11,643 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were acquired at an average price of GBX 138 ($1.71) per share, for a total transaction of £16,067.34 ($19,954.47).

Diaceutics Price Performance

LON:DXRX opened at GBX 135.05 ($1.68) on Friday. Diaceutics PLC has a 12 month low of GBX 92.24 ($1.15) and a 12 month high of GBX 151 ($1.88). The company’s 50-day moving average price is GBX 129.50 and its two-hundred day moving average price is GBX 128.53. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The firm has a market cap of £114.08 million, a PE ratio of -4,501.67 and a beta of 0.58.

Analyst Ratings Changes

A number of research analysts have commented on DXRX shares. Canaccord Genuity Group restated a “buy” rating and set a GBX 160 ($1.99) price target on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 160 ($1.99) price target on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.